| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CMC4 |
| Uniprot No | P56277 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-68aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSEFMPQKD PCQKQACEIQ KCLQANSYME SKCQAVIQEL RKCCAQYPKG RSVVCSGFEK EEEENLTRKS ASK |
| 预测分子量 | 10 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的关于CMC4重组蛋白的参考文献示例(非真实文献)：
---
1. **《Structural Analysis of CMC4 Recombinant Protein in Membrane Channel Formation》**
*Author: Zhang, L.; et al.*
**摘要**: 本研究通过X射线晶体学解析了CMC4重组蛋白的三维结构，揭示了其跨膜螺旋结构与离子通道形成的关键区域，为靶向药物设计提供结构基础。
2. **《Functional Characterization of CMC4 in Calcium Signaling Pathways》**
*Author: Smith, R.J.; Patel, K.*
**摘要**: 通过基因敲除和过表达实验，验证了CMC4重组蛋白在细胞钙离子稳态调控中的作用，发现其缺陷可导致线粒体功能异常及细胞凋亡通路激活。
3. **《High-Yield Production of CMC4 Recombinant Protein Using Pichia Pastoris System》**
*Author: Yamamoto, H.; et al.*
**摘要**: 开发了一种基于毕赤酵母表达系统的CMC4重组蛋白高效生产方法，优化发酵条件后蛋白产量达1.2 g/L，纯度>95%，适用于规模化制备。
4. **《CMC4 as a Therapeutic Target in Autoimmune Diseases: Preclinical Evidence》**
*Author: García, M.; López, C.*
**摘要**: 动物实验表明，CMC4重组蛋白可通过抑制TLR4/NF-κB通路减轻类风湿性关节炎模型中的炎症反应，提示其作为新型免疫调节剂的潜力。
---
注：以上内容为模拟生成，如需真实文献建议通过PubMed、ScienceDirect等数据库检索关键词(如“CMC4 recombinant protein”或结合具体研究领域)。
CMC4 recombinant protein is a bioengineered molecule designed to mimic specific functional domains of naturally occurring proteins involved in cellular adhesion, signaling, or structural support. Typically, "CMC4" refers to a customized construct that integrates critical motifs from extracellular matrix (ECM) proteins or cell-surface receptors, optimized for enhanced stability, solubility, and biological activity. Such recombinant proteins are synthesized using heterologous expression systems like mammalian cells (e.g., CHO or HEK293), bacteria, or yeast, followed by purification via affinity chromatography to ensure high purity.
The design of CMC4 often targets applications in regenerative medicine, drug delivery, or biomedical research. For instance, it may incorporate sequences from collagen, fibronectin, or laminin to promote cell adhesion, proliferation, or tissue repair. In cancer research, CMC4 derivatives might include tumor-targeting domains or immune-modulating epitopes to enhance therapeutic specificity. Its recombinant nature allows precise control over structural features, reducing batch-to-batch variability compared to native proteins.
Preclinical studies of CMC4-like proteins highlight their potential in wound healing, 3D tissue scaffolding, or as coatings for medical implants to improve biocompatibility. Additionally, they serve as tools to study protein-protein interactions or receptor activation mechanisms. Safety profiles are rigorously assessed to minimize immunogenicity, a common challenge with recombinant biologics.
Innovations in protein engineering, such as site-specific mutagenesis or fusion tags (e.g., Fc regions for prolonged half-life), further refine CMC4’s functionality. As a modular platform, it exemplifies the convergence of structural biology and translational medicine, offering tailored solutions for unmet clinical needs while adhering to regulatory standards for therapeutic development.
×
